Pharmaron has signed an agreement to provide Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) with nucleoside phosphoramidites at quantities up to 100 kg. Nucleoside phosphoramidites are fundamental building blocks in the production of antisense therapeutics. Isis is the world's leader in antisense therapeutics with a pipeline of 24 drugs in development.
Under the terms of this contract, Pharmaron will continue to provide Isis with certain nucleoside phosphoramidites during the next two years. Pharmaron has worked closely with Isis' R&D team over the past three years and also provided high-quality materials for early discovery work.
"We have had a very successful working relationship with Pharmaron and are pleased to continue this partnership for two more years. Pharmaron has been an outstanding supplier of high-quality nucleoside phosphoramidites to Isis. The dependability and quality of the materials Pharmaron supplies to us allow us to focus our efforts on advancing our chemistries and technologies," said Eric Swayze, Ph.D., Vice President, Medicinal Chemistry at Isis.
"Pharmaron is honored to continue to work with Isis Pharmaceuticals, a true pioneer and leader in the field of antisense therapeutics," said Pharmaron Chairman and CEO Dr. Boliang Lou. "Our customers have come to depend on our high-quality R&D services, which we provide to pharmaceutical and biotech companies around the world."
Study finds patients with long COVID exhibit complement dysregulation with signs of thromboinflammation